Lead Product(s) : PENAO,Sirolimus
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : PENAO Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
Details : This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed.
Brand Name : PENAO
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : PENAO,Sirolimus
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : PENAO Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.